9L1K | pdb_00009l1k

sdAbA YERLS mutant


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.57 Å
  • R-Value Free: 
    0.170 (Depositor), 0.177 (DCC) 
  • R-Value Work: 
    0.136 (Depositor), 0.149 (DCC) 

Starting Model: in silico
View more details

wwPDB Validation   3D Report Full Report


This is version 1.0 of the entry. See complete history


Literature

Improving the solubility of single domain antibodies using VH-like hallmark residues.

Uto, Y.Nakakido, M.Yokoo, T.Fernandez-Perez, J.Entzminger, K.Maruyama, T.Okumura, C.J.Kuroda, D.Caaveiro, J.M.M.Tsumoto, K.

(2025) Protein Sci 34: e70189-e70189

  • DOI: https://doi.org/10.1002/pro.70189
  • Primary Citation of Related Structures:  
    9L1J, 9L1K

  • PubMed Abstract: 

    Single domain antibodies (sdAbs) can be generated from variable regions of heavy-chain antibodies, which lack light chain and CH1 region. They have attracted attention due to their small size and molecular characteristics. Hydrophilic hallmark amino acids at framework region 2 (FR2) are key residues involved in the solubility of sdAbs. Nevertheless, previous studies reported that several sdAbs with human VH-like hydrophobic hallmark residues were soluble in a monomeric state and suggested that solubility also depends on the amino acid sequences in the complementarity-determining region. In this study, we obtained two sdAbs (sdAb A and B) with VH-like hallmark residues and low solubility from an alpaca immune library. We introduced VHH-like mutations (V37Y, G44E, L45R, W47L) into the hallmark residues in FR2 of both sdAb A and B. We were able to prepare sdAb A as a monomer without an additive in the buffer, but sdAb B was polydispersed when arginine was not added to the buffer. We also predicted the hydrophobicity of the sdAb B surface by spatial aggregation propensity calculations and identified W99 as the residue responsible for its low solubility. Subsequently, we obtained the sdAb B mutant as a monomer by introducing the W99A mutation. We characterized the engineered sdAbs using structural, physicochemical, and biophysical analyses and found that the solubility-improved sdAbs retained their functionality. Our findings can be applied to improving the solubility of sdAbs even in the absence of structural information.


  • Organizational Affiliation
    • Department of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, Tokyo, Japan.

Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
sdAbA YERLS mutant
A, B, C, D
126Vicugna pacosMutation(s): 0 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 3 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download Ideal Coordinates CCD File 
E [auth A]
G [auth B]
H [auth B]
I [auth C]
K [auth D]
E [auth A],
G [auth B],
H [auth B],
I [auth C],
K [auth D],
L [auth D],
M [auth D],
N [auth D]
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
GOL
Query on GOL

Download Ideal Coordinates CCD File 
J [auth C],
O [auth D],
P [auth D]
GLYCEROL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
NA
Query on NA

Download Ideal Coordinates CCD File 
F [auth A],
Q [auth D]
SODIUM ION
Na
FKNQFGJONOIPTF-UHFFFAOYSA-N
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.57 Å
  • R-Value Free:  0.170 (Depositor), 0.177 (DCC) 
  • R-Value Work:  0.136 (Depositor), 0.149 (DCC) 
Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 52.393α = 90
b = 113.251β = 90
c = 113.938γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Japan Society for the Promotion of Science (JSPS)Japan21H05090
Japan Society for the Promotion of Science (JSPS)Japan20H02531
Japan Agency for Medical Research and Development (AMED)JapanJP19am0401010h
Japan Agency for Medical Research and Development (AMED)JapanJP23tk0124002h
Japan Agency for Medical Research and Development (AMED)JapanJP223fa627001
Japan Agency for Medical Research and Development (AMED)JapanJP223fa727002
Japan Agency for Medical Research and Development (AMED)JapanJP22ama121033

Revision History  (Full details and data files)

  • Version 1.0: 2025-08-27
    Type: Initial release